Insulet, an innovative medical device company, has received FDA approval for its Omnipod Go system. Unlike Medtronic’s MimMed 780G pump, which also received FDA approval this week, the Omnipod Go system is for use by patients with Type 2 diabetes.

Each pod can hold enough insulin to last up to 72 hours. Additionally, the Go system does not connect to a smartphone or standalone controller. It works independently throughout each three-day shift, delivering continuous rapid-acting insulin according to one of seven preprogrammed daily rates.

Click here to read the entire article.